GSK and Pfizer sign $450 million vaccine contract for developing countries
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Pfizer will both supply their respective pneumococcal conjugate vaccines (PCV) at a massive discount to the prices charged in industrialised markets to a scheme that aims to save the lives of 900,000 children in the world's poorest countries by 2015.